Upgrade to SI Premium - Free Trial

Faeth Therapeutics (FTH) Reiterated at Market Outperform by Citizens After KOL Discussion

October 21, 2026 5:51 AM
Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $51.00 price target on Faeth Therapeutics (NASDAQ: FTH).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments